Introduction: Our study aims to observe the effect of mesenchymal stem cells (MSCs) in lowering amyloid accumulation and ryanodine receptor 3 (RYR3) gene expression, further improving cognitive dysfunction in Alzheimer's disease (AD).
Methods: Twenty male adult Wistar rats were randomly distributed into three groups of animals ( = 5). The AlCl group was given 300 mg/kg body weight (BW) of AlCl intraperitoneally for 5 days, further the MSC injection, and their effect after 30 days was observed.
Results: MSCs improved amyloid accumulation and Y-maze scores, and expression of the RYR3 gene decreased compared to the control group.
Conclusions: MSCs improved amyloid accumulation, Y-maze scores, and RYR3 expression in the AD animal model.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259384 | PMC |
| http://dx.doi.org/10.5114/aoms/163353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The CD74 inhibitor DRhQ improves short-term memory and mitochondrial function in 5xFAD mouse model of Aβ accumulation.
Metab Brain Dis
January 2025
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Neuroinflammation and mitochondrial dysfunction are early events in Alzheimer's disease (AD) and contribute to neurodegeneration and cognitive impairment. Evidence suggests that the inflammatory axis mediated by macrophage migration inhibitory factor (MIF) binding to its receptor, CD74, plays an important role in many central nervous system (CNS) disorders such as AD. Our group has developed DRhQ, a novel CD74 binding construct which competitively inhibits MIF binding, blocks macrophage activation and migration into the CNS, enhances anti-inflammatory microglia cell numbers and reduces pro-inflammatory gene expression.
View Article and Find Full Text PDFCognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure.
Alzheimers Dement
January 2025
Department of Neuroscience, University of California, Berkeley, California, USA.
Introduction: Successful cognitive aging is related to both maintaining brain structure and avoiding Alzheimer's disease (AD) pathology, but how these factors interplay is unclear.
Methods: A total of 109 cognitively normal older adults (70+ years old) underwent amyloid beta (Aβ) and tau positron emission tomography (PET) imaging, structural magnetic resonance imaging (MRI), and cognitive testing. Cognitive aging was quantified using the cognitive age gap (CAG), subtracting chronological age from predicted cognitive age.
Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's-related phenotypes.
Alzheimers Dement
January 2025
Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, The First Affiliated Hospital and Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction: Interferon-induced transmembrane protein 3 (IFITM3) modulates γ-secretase in Alzheimer's Disease (AD). Although IFITM3 knockout reduces amyloid β protein (Aβ) production, its cell-specific effect on AD remains unclear.
Methods: Single nucleus RNA sequencing (snRNA-seq) was used to assess IFITM3 expression.
Impact and Significance of Viral Vectors for siRNA Delivery in the Treatment of Alzheimer's Disease.
Curr Pharm Biotechnol
January 2025
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT & Po Piparia, Waghodia, Vadodara, Gujarat, India.
Alzheimer's disease (AD) remains a major challenge in developing effective treatments due to its complex pathophysiology, including the accumulation of amyloid-beta plaques and tau tangles. Small interfering RNA (siRNA) technology offers promise for targeted gene silencing, but effective delivery to the central nervous system remains a significant obstacle. Viral vectors have emerged as potent delivery vehicles for transporting siRNA to neural tissues.
View Article and Find Full Text PDFHuman serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease.
J Control Release
January 2025
College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea. Electronic address:
Alzheimer's disease (AD) is the most commonly occurring brain disorder, characterized by the accumulation of amyloid-β (Aβ) and tau, subsequently leading to neurocognitive decline. 3-Amino-1-propanesulfonic acid (TPS) and its prodrug, currently under clinical trial III, serve as promising therapeutic agents targeting Aβ pathology by specifically preventing monomer-to-oligomer formation. Inspired by the potency of TPS prodrug, we hypothesized that conjugating TPS with human serum albumin (HSA) could enhance brain delivery and synergistically inhibit Aβ aggregation in mild to moderate AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!